Shulov Innovative Science Ltd. (SIS) was founded by the late Prof. Aharon Shulov and Mr. Aviv Marx.
Aharon Shulov was a Professor at the Hebrew University in Jerusalem and a world-renown expert in animal venom.
Professor Shulov served as the director of the Jerusalem zoo for 43 years until his retirement.
Moreover, he was head of the Zoology Department at the Hebrew University for 30 years. Aviv Marx is an entrepreneur and
a businessman from the Israeli city of Rehovot. 
Currently, Shulov innovative Science (SIS) is an advanced clinical-stage biopharmaceutical company focusing on developing New Chemical Entities (NCE’s) for a variety of therapeutic uses. The NCE’s are short synthetic peptides with a unique pharmacological activity of combined potency as an effective anti-inflammatory, anti-viral, and analgesic agent.
Multiple strong patents protect SIS’s platform technology.

Proof of Concept: SIS – Institute for Venom Research

During its early days, SIS Investigated the snake venom to find an analgesic component based on the natural compounds within the venom. Using various analytical methods, the molecular structure of the analgesic element was elucidated as a New Chemical Entity (NCE). This is a short peptide that includes 3-4 amino acids branded as ZEP-3 and ZEP-4. From that point onward, the company has defined the peptide as traceable and reproducible. It was synthesized up to a large scale following complete GMP requirements.

SIS – An advanced clinical-stage biopharmaceutical company

Since 2004, SIS has been working on pre-clinical and clinical development, leading to an advanced clinical-stage biopharmaceutical company, focusing on the development of NCE’s for therapeutic uses as anti-inflammatory, anti-viral, and analgesic agents. The NCE’s under development are short synthetic peptides branded as ZEP-3 and ZEP-4, and both molecules possess the unique biological activity and potent therapeutic use for a wide range of clinical indications.
The company completed a Phase II clinical study in Herpes Labialis (Cold sores) – See the “Clinical Trials”
section for a detailed report.
SIS has approached the FDA in preparation for a pre-IND meeting to secure an IND submission for an advanced Phase III clinical trial in Herpes Labialis patients in the US. It is the next step towards regulatory approval for the marketing and commercialization
of its lead compound.
In addition, SIS conducts a Phase II clinical study in Atopic Dermatitis (AD), a common and underserved dermatological disorder, in 9 clinical sites at the leading dermatology departments at hospitals and community clinics in Israel.
SIS is developing additional clinical indications such as Herpes Zoster, Genital Herpes, Burns, and Lung Inflammation. Pre-clinical work is complete, and the company is ready to start a Phase I/II study on each of these indications.